X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The Company intends to use the net proceeds for research and development of its pipeline of novel program to treat several inflammatory disorders using anti-TNF (tumor necrosis factor), including adalimumab for the treatment of early-stage Dupuytren’s disease.
Lead Product(s): Adalimumab
Therapeutic Area: Musculoskeletal Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Alliance Global Partners
Deal Size: $3.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering August 14, 2023
Details:
The Company intends to use the net proceeds for research and development of its pipeline of novel program to treat several inflammatory disorders using anti-TNF (tumor necrosis factor), including adalimumab for the treatment of early-stage Dupuytren’s disease.
Lead Product(s): Adalimumab
Therapeutic Area: Musculoskeletal Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Alliance Global Partners
Deal Size: $3.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering August 10, 2023
Details:
The agreement aims to perform a clinical pharmacology study of the uptake of cannabidiol (CBD) in a formulation which can be delivered as a pill orally.
Lead Product(s): Cannabidiol
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Hebrew University
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement August 07, 2023
Details:
Adalimumab, anti-TNF therapeutic, approved and used under the brand name Humira for several autoimmune conditions, is being developed for the treatment of early-stage Dupuytren’s Contracture.
Lead Product(s): Adalimumab
Therapeutic Area: Musculoskeletal Product Name: Humira
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 03, 2023
Details:
The Company intends to use the net proceeds from the offering for research and development of Humira (adalimumab), a tumor necrosis factor (TNF) blocker, for the treatment of Dupuytren Contracture.
Lead Product(s): Adalimumab
Therapeutic Area: Musculoskeletal Product Name: Humira
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Alliance Global Partners
Deal Size: $3.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering April 10, 2023
Details:
The Company intends to use the net proceeds from the offering for research and development of Humira (adalimumab), a tumor necrosis factor (TNF) blocker, for the treatment of Dupuytren Contracture.
Lead Product(s): Adalimumab
Therapeutic Area: Musculoskeletal Product Name: Humira
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Alliance Global Partners
Deal Size: $3.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering April 05, 2023
Details:
Adalimumab binds with specificity to tumor necrosis factor-alpha (TNF-alpha) and inhibits its interaction with the p55 and p75 cell surface TNF receptors. Currently being developed for early stage dupuytren’s disease.
Lead Product(s): Adalimumab
Therapeutic Area: Dermatology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 23, 2023
Details:
Adalimumab binds with specificity to tumor necrosis factor-alpha (TNF-alpha) and inhibits its interaction with the p55 and p75 cell surface TNF receptors. Currently being developed for early stage dupuytren’s disease.
Lead Product(s): Adalimumab
Therapeutic Area: Dermatology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 25, 2023
Details:
Adalimumab is a monoclonal anti-tumor necrosis factor alpha antibody used in the treatment of a wide variety of inflammatory conditions such as rheumatoid arthritis, crohn's disease, and ankylosing spondylitis.
Lead Product(s): Adalimumab
Therapeutic Area: Dermatology Product Name: Undisclosed
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Alliance Global Partners
Deal Size: $6.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering December 23, 2022
Details:
Research at Oxford University has indicated an anti-TNF mechanism of Adalimumab can slow or prevent the proliferation of myoblast cells that lead to the formation and growth of the fibrous nodules/cords in the palm and possible finger contracture.
Lead Product(s): Adalimumab
Therapeutic Area: Dermatology Product Name: Undisclosed
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Alliance Global Partners
Deal Size: $6.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering December 20, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
